JP7860103B2 - 複素環式スピロ化合物及びその使用方法 - Google Patents
複素環式スピロ化合物及びその使用方法Info
- Publication number
- JP7860103B2 JP7860103B2 JP2023524901A JP2023524901A JP7860103B2 JP 7860103 B2 JP7860103 B2 JP 7860103B2 JP 2023524901 A JP2023524901 A JP 2023524901A JP 2023524901 A JP2023524901 A JP 2023524901A JP 7860103 B2 JP7860103 B2 JP 7860103B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- diazaspiro
- methyl
- octan
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/123913 | 2020-10-27 | ||
| CN2020123913 | 2020-10-27 | ||
| PCT/US2021/056702 WO2022093856A1 (en) | 2020-10-27 | 2021-10-26 | Heterocyclic spiro compounds and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549055A JP2023549055A (ja) | 2023-11-22 |
| JP2023549055A5 JP2023549055A5 (cg-RX-API-DMAC7.html) | 2024-11-05 |
| JP7860103B2 true JP7860103B2 (ja) | 2026-05-15 |
Family
ID=78650109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524901A Active JP7860103B2 (ja) | 2020-10-27 | 2021-10-26 | 複素環式スピロ化合物及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230406860A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4237086A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7860103B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021370660A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3199082A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004802A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022093856A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| WO2022066805A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| CA3227138A1 (en) | 2021-07-23 | 2023-01-26 | Theras, Inc. | Compositions and methods for inhibition of ras |
| AR128211A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| AR128212A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| CN117186107A (zh) * | 2022-05-31 | 2023-12-08 | 成都先导药物开发股份有限公司 | 一种制备2-取代-5,7-二羰基-2,6-二氮杂螺[3,4]辛烷中间体的方法 |
| AU2023377064A1 (en) | 2022-11-09 | 2025-05-22 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| TW202615038A (zh) | 2024-08-07 | 2026-04-16 | 美商太斯萊特醫藥美國有限責任公司 | 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物 |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014507458A (ja) | 2011-03-11 | 2014-03-27 | グラクソ グループ リミテッド | Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体 |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| WO2020028706A1 (en) | 2018-08-01 | 2020-02-06 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| WO2020113071A1 (en) | 2018-11-29 | 2020-06-04 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080540A1 (es) | 2006-08-10 | 2008-06-08 | Glaxo Group Ltd | Compuestos 4-fenil-2-piridinil-metil sustituidos como moduladores de los canales de sodio con apertura por voltaje |
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| AU2019401495B2 (en) | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| AU2019404576B2 (en) | 2018-12-20 | 2025-07-17 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| IL283639B2 (en) | 2018-12-20 | 2024-06-01 | Amgen Inc | Kif18a inhibitors |
| MA54550A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
-
2021
- 2021-10-26 WO PCT/US2021/056702 patent/WO2022093856A1/en not_active Ceased
- 2021-10-26 CA CA3199082A patent/CA3199082A1/en active Pending
- 2021-10-26 MX MX2023004802A patent/MX2023004802A/es unknown
- 2021-10-26 US US18/033,439 patent/US20230406860A1/en active Pending
- 2021-10-26 AU AU2021370660A patent/AU2021370660A1/en active Pending
- 2021-10-26 EP EP21810231.7A patent/EP4237086A1/en active Pending
- 2021-10-26 JP JP2023524901A patent/JP7860103B2/ja active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014507458A (ja) | 2011-03-11 | 2014-03-27 | グラクソ グループ リミテッド | Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体 |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| WO2020028706A1 (en) | 2018-08-01 | 2020-02-06 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| WO2020113071A1 (en) | 2018-11-29 | 2020-06-04 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230406860A1 (en) | 2023-12-21 |
| AU2021370660A1 (en) | 2023-06-08 |
| JP2023549055A (ja) | 2023-11-22 |
| CA3199082A1 (en) | 2022-05-05 |
| MX2023004802A (es) | 2023-06-22 |
| WO2022093856A1 (en) | 2022-05-05 |
| EP4237086A1 (en) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7654071B2 (ja) | 複素環スピロ化合物及び使用方法 | |
| JP2023549055A (ja) | 複素環式スピロ化合物及びその使用方法 | |
| US20250059205A1 (en) | Heterocyclic Compounds and Methods of Use | |
| JP2024532735A (ja) | 複素環式化合物及び使用方法 | |
| JP2024532733A (ja) | 複素環式化合物及び使用方法 | |
| JP2025508702A (ja) | キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用 | |
| JP2024532734A (ja) | 複素環式化合物及び使用方法 | |
| JP2025508703A (ja) | キナゾリン化合物及びそれらの変異krasタンパク質の阻害剤としての使用 | |
| JP2024517693A (ja) | 2-アミノベンゾチアゾール化合物及びその使用方法 | |
| AU2022219987A1 (en) | Cdk inhibitors and methods of use thereof | |
| JP2025535046A (ja) | Kras g12c変異タンパク質の複素環阻害剤及びその使用 | |
| AU2018201557A1 (en) | Heteroaryl pyridone and aza-pyridone compounds as inhibitors of Btk activity | |
| AU2015320142B2 (en) | Novel imidazopyridazine compounds and their use | |
| JP2016537384A (ja) | ピロロピロロン誘導体およびbet阻害剤としてのその使用 | |
| CN105732637B (zh) | 杂芳化合物及其在药物中的应用 | |
| US12534479B2 (en) | Triazine compound and composition and use thereof | |
| CN116249696B (zh) | 嘧啶酮类化合物及其用途 | |
| CN117897159A (zh) | 杂环化合物及使用方法 | |
| CN117835976A (zh) | 杂环化合物及使用方法 | |
| CA3143350A1 (en) | Small molecule inhibitors of nf-kb inducing kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241025 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241025 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250908 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250910 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260309 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260331 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260430 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7860103 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |